"The
Report Opportunity Analyzer: Chronic Lymphocytic Leukemia -
Opportunity Analysis and Forecasts to 2018 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
Chronic
lymphocytic leukemia (CLL), the most common form of adult leukemia,
is caused by the uncontrolled proliferation of B lymphocytes (a type
of white blood cell) in the bone marrow, blood and lymphoid tissues.
This report focuses on the current treatment landscape, unmet needs,
pipeline and commercial opportunity in the CLL market with coverage
of both the first-line and relapsed/refractory settings. While the
current standard of care consists of chemoimmunotherapy, CLL disease
management is poised for dramatic changes, particularly in the
treatment of relapsed/refractory and elderly patients, as four new
drugs (Gazyva, Imbruvica, idelalisib and IPI-145) will launch during
the forecast period. As they address large unmet needs, GlobalData
expects these premium-priced new drugs will have rapid uptake driving
the overall CLL market and contributing to over 70% of total market
sales by 2018.
View Report At
:http://www.marketresearchreports.biz/analysis/210562
Highlights
Key Questions Answered
-
Which CLL patients have the greatest unmet needs and how well will
these needs be addressed by the new agents?
-
How will CLL disease management change as new agents enter the
market?
-
What are the R&D and clinical trial design strategies pursued by
companies in the CLL space?
-
What are the most promising late-stage pipeline agents for CLL? How
do their clinical and commercial attributes compare to one another
and the current standards of care?
-
What opportunities will remain for future players following the
launch of these pipeline agents?
-
What exciting, innovative approaches are being investigated in the
early-stage CLL pipeline?
Key Findings
-
The CLL market, in the 6MM is forecasted to rapidly increase from
$1.4bn in 2013 to $3.3bn in 2018, at a CAGR of 18.8%. This growth
will be driven by the launch and adoption of four new premium-priced
drugs during the forecast period, including Gazyva, Imbruvica,
idelalisib and IPI-145.
-
GlobalData expects there will be rapid uptake of the new agents in
the relapsed/refractory setting, particularly in those patients who
do not have a good response to first-line treatment. In the
first-line setting, GlobalData foresees a slower uptake of the new
agents, particularly among fit patients who can enjoy lengthy and
deep remissions from the current standard of care
chemoimmunotherapy-based regimens.
-
Among the new agents, GlobalData expects Imbruvica and idelalisib
will dominate patient share and will account for more than 60% of all
total sales in 2018 and drive 100% of total market growth. However,
in GlobalDatas assessment, idelalisibs use in combination with
Rituxan and its overall stronger clinical development program will
help it emerge as the market leader in the relapsed/refractory
setting by 2018.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/210562
Scope
- Key countries covered: US,
France, Germany, Italy, Spain, and UK
- Overview of CLL, including
epidemiology, etiology, pathophysiology, clinical staging, symptoms,
quality of life, and disease management.
- Topline CLL therapeutics
market revenue from 2013-2018. Annual cost of therapy, and major
marketed and pipeline drug sales in this forecast period are
included.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, R&D strategies, and clinical trial design for the CLL
market.
- Pipeline analysis:
comprehensive data split across different phases, emerging novel
trends under development, synopses of innovative early-stage
projects, and detailed analysis of late-stage pipeline drugs. An
interactive clinical and commercial analyzer tool is available.
- Analysis of the current and
future market competition in the 6MM CLL therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies
by understanding the trends shaping and driving the 6MM CLL market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the 6MM CLL
therapeutics market in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Follow us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Table
of Contents
1
Table of Contents
1
Table of Contents 8
1.1
List of Tables 12
1.2
List of Figures 15
2
Introduction 16
2.1
Catalyst 16
2.2
Related Reports 16
2.3
Upcoming Related Reports 17
3
Disease Overview 18
3.1
Etiology 18
3.2
Pathophysiology 18
3.3
Staging and Prognostic Markers 19
3.3.1
Rai and Binet Staging System 19
3.3.2
Chromosomal Abnormalities and Other Prognostic Markers 20
3.4
Symptoms 21
3.5
Quality of Life 22
4
Disease Management 23
4.1
Diagnosis 23
4.2
Treatment Overview 23
4.2.1
First-Line Treatment 25
4.2.2
Second-Line Treatment and Beyond 26
4.3
Response Criteria for Evaluating the Treatment Outcome 26
5
Epidemiology 28
5.1
Disease Background 28
5.2
Risk Factors and Comorbidities 29
5.3
Global Trends 31
5.3.1
Incidence 31
5.3.2
Survival from CLL - US and 5EU 34
5.4
Forecast Methodology 34
5.4.1
Sources Used 36
5.4.2
Sources Not Used 38
5.4.3
Forecast Assumptions and Methods, Diagnosed Incident Cases 38
5.4.4
Forecast Assumptions and Methods, 5-Year Diagnosed Prevalent Cases 40
5.4.5
Forecast Assumptions and Methods, Rai Stage at Diagnosis 40
5.5
Epidemiological Forecast for CLL (2013-2023) 41
5.5.1
Diagnosed Incident Cases of CLL 41
5.5.2
Age-Specific Diagnosed Incident Cases of CLL 42
5.5.3
Sex-Specific Diagnosed Incident Cases of CLL 44
5.5.4
Age-Standardized Diagnosed Incidence of CLL 45
5.5.5
5-Year Diagnosed Prevalent Cases of CLL 46
5.5.6
Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis 48
5.6
Discussion 48
5.6.1
Epidemiological Forecast Insight 48
5.6.2
Limitations of the Analysis 49
5.6.3
Strengths of the Analysis 50
6
Current Treatment Options 51
6.1
Overview 51
Read our latest Press
Release at http://www.marketresearchreports.biz/pressreleases
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment